{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:31:19Z","timestamp":1793773879184,"version":"4.6.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377083"],"award-info":[{"award-number":["22377083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118332","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:36:23Z","timestamp":1761982583000},"page":"118332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"P2","title":["FXR-targeted drug discovery: Recent advances and therapeutic perspectives"],"prefix":"10.1016","volume":"302","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-5943","authenticated-orcid":false,"given":"Wu-Yu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhai","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118332_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective Farnesoid X Receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118332_bib2","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1021\/acs.jmedchem.1c01017","article-title":"Recent advances in the medicinal chemistry of Farnesoid X receptor","volume":"64","author":"Fang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118332_bib3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"issue":"5418","key":"10.1016\/j.ejmech.2025.118332_bib4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118332_bib5","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/pro.3496","article-title":"The nuclear receptor superfamily: a structural perspective","volume":"27","author":"Weikum","year":"2018","journal-title":"Protein Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118332_bib6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1042\/EBC20210020","article-title":"Nuclear receptors: from molecular mechanisms to therapeutics","volume":"65","author":"Frigo","year":"2021","journal-title":"Essays Biochem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/aps.2014.133","article-title":"A structural perspective on nuclear receptors as targets of environmental compounds","volume":"36","author":"Delfosse","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118332_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s13105-025-01118-2","article-title":"FXR crosstalk with other nuclear receptors","author":"Mohammed","year":"2025","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2025.118332_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/bs.pmbts.2022.07.014","article-title":"Nuclear receptor: structure and function","volume":"196","author":"Sar","year":"2023","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-physiol-021909-135917","article-title":"Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics","volume":"72","author":"Huang","year":"2010","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118332_bib12","first-page":"621","article-title":"FXR, a target for different diseases","volume":"23","author":"Wang","year":"2008","journal-title":"Histol. Histopathol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","article-title":"Steroidal or non-steroidal FXR agonists - is that the question?","volume":"66","author":"Verbeke","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118332_bib14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2025.118332_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"issue":"10215","key":"10.1016\/j.ejmech.2025.118332_bib16","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118332_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172661","article-title":"Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis","volume":"863","author":"Venetsanaki","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118332_bib18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molmed.2007.06.001","article-title":"Targeting farnesoid X receptor for liver and metabolic disorders","volume":"13","author":"Fiorucci","year":"2007","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118332_bib19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/MCB.23.3.864-872.2003","article-title":"Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol","volume":"23","author":"Otte","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118332_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","article-title":"FXR, a multipurpose nuclear receptor","volume":"31","author":"Lee","year":"2006","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/molbev\/msm251","article-title":"Analysis of nuclear receptor pseudogenes in vertebrates: how the silent tell their stories","volume":"25","author":"Zhang","year":"2008","journal-title":"Mol. Biol. Evol."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.118332_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-1119(02)00557-7","article-title":"Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters","volume":"290","author":"Huber","year":"2002","journal-title":"Gene"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118332_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tem.2011.07.002","article-title":"Hepatic FXR: key regulator of whole-body energy metabolism","volume":"22","author":"Teodoro","year":"2011","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118332_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115028","article-title":"Hepatic farnesoid X-receptor isoforms \u03b12 and \u03b14 differentially modulate bile salt and lipoprotein metabolism in mice","volume":"9","author":"Boesjes","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural structural variants of the nuclear receptor Farnesoid X receptor affect transcriptional activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib26","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl. Recept. Signal."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"Genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118332_bib28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bbadis.2010.11.011","article-title":"Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications","volume":"1812","author":"Kemper","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hep.22661","article-title":"Low retinol levels differentially modulate bile salt\u2013induced expression of human and mouse hepatic bile salt transporters","volume":"49","author":"Hoeke","year":"2009","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118332_bib30","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1074\/jbc.275.15.10918","article-title":"Farnesoid X receptor responds to bile acids and represses cholesterol 7\u03b1-Hydroxylase gene (CYP7A1) transcription","volume":"275","author":"Chiang","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","article-title":"Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress","volume":"37","author":"Song","year":"2025","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118332_bib32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118332_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol. Int."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118332_bib35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory Cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol. Int."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118332_bib37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","article-title":"Fatty liver diseases, bile acids, and FXR","volume":"6","author":"Zhu","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118332_bib38","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118332_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/nu11122904","article-title":"Evidence that Calebin A, a component of Curcuma Longa suppresses NF-B mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-\u03b2 (Lymphotoxin)","volume":"11","author":"Buhrmann","year":"2019","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118332_bib41","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1182\/blood-2007-01-067256","article-title":"Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis","volume":"109","author":"Kunnumakkara","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118332_bib42","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.cellsig.2012.04.015","article-title":"FXR ligands protect against hepatocellular inflammation via SOCS3 induction","volume":"24","author":"Xu","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2025.118332_bib43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile acids and FXR: novel targets for liver diseases","volume":"7","author":"Stofan","year":"2020","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2025.118332_bib45","first-page":"89","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection","author":"Bowlus","year":"2016","journal-title":"Hepat Med"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118332_bib46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","article-title":"FXR, a multipurpose nuclear receptor","volume":"31","author":"Lee","year":"2006","journal-title":"Trends Biochem. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118332_bib47","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118332_bib48","first-page":"92","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2016","journal-title":"Minerva Endocrinol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s43556-021-00035-2","article-title":"Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer","volume":"2","author":"Girisa","year":"2021","journal-title":"Mol Biomed"},{"key":"10.1016\/j.ejmech.2025.118332_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111543","article-title":"Pleiotropic roles of FXR in liver and colorectal cancers","volume":"543","author":"Huang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118332_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/aps.2014.117","article-title":"FXR and liver carcinogenesis","volume":"36","author":"Huang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118332_bib53","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","article-title":"FXR regulates intestinal cancer stem cell proliferation","volume":"176","author":"Fu","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118332_bib54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118332_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117082","article-title":"Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold","volume":"282","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116280","article-title":"Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver\/blood ratio","volume":"43","author":"Tang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118332_bib57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/acsmedchemlett.1c00198","article-title":"Discovery of BMS-986318, a potent Nonbile acid FXR agonist for the treatment of nonalcoholic steatohepatitis","volume":"12","author":"Carpenter","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118332_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128993","article-title":"Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists","volume":"76","author":"Zhu","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118332_bib59","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1021\/acs.jmedchem.3c00456","article-title":"Discovery of HPG1860, a structurally novel Nonbile acid FXR agonist currently in clinical development for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Mo","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118332_bib60","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1021\/acs.jmedchem.0c01065","article-title":"Discovery and optimization of non-bile acid FXR agonists as preclinical candidates for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118332_bib61","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1021\/acs.jmedchem.3c02304","article-title":"Discovery and optimization of novel Nonbile acid FXR agonists as preclinical candidates for the treatment of inflammatory bowel disease","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118332_bib62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118332_bib63","doi-asserted-by":"crossref","first-page":"8948","DOI":"10.1021\/acs.jmedchem.2c00165","article-title":"Discovery of BMS-986339, a pharmacologically differentiated farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis","volume":"65","author":"Nara","year":"2022","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118332_bib64","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/acs.jmedchem.2c00641","article-title":"Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic acid methyl ester, an Intestine-Specific, FXR partial agonist for the treatment of nonalcoholic steatohepatitis","volume":"65","author":"Shim","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107071","article-title":"Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease","volume":"143","author":"Huang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-291X(03)00551-5","article-title":"Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene","volume":"304","author":"Owsley","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118332_bib68","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/mol.104.007054","article-title":"The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand","volume":"67","author":"Burris","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118332_bib69","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1021\/jm0505056","article-title":"Is antagonism of E\/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study","volume":"48","author":"Meyer","year":"2005","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118332_bib70","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118332_bib71","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acsmedchemlett.7b00318","article-title":"Synthesis and biological evaluation of a series of bile acid derivatives as FXR agonists for treatment of NASH","volume":"8","author":"Xiao","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118332_bib72","series-title":"Preparation of Obeticholic Acid Taurine Conjugate Monopotassium Salt Useful as Farnesoid X Receptor Agonist","author":"Yuan","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118332_bib73","series-title":"Obeticholic Acid Amide Derivative as FXR Agonist","author":"Yuan","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118332_bib74","series-title":"Farnesoid X Receptor Agonist and its Preparation","author":"Yuan","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118332_bib75","series-title":"Bile Acid Derivatives as FXR Agonists and Methods of Use Thereof","author":"Wang","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118332_bib76","series-title":"Preparation of Fluorinated Bile Acid Derivatives as Farnesoid X Receptor Agonists","author":"Weymouth-Wilson","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118332_bib77","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118332_bib78","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1021\/jm901390p","article-title":"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity","volume":"52","author":"Pellicciari","year":"2009","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118332_bib79","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118332_bib80","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1002\/anie.201202059","article-title":"An unexpected and significantly lower hydrogen-bond-donating capacity of fluorohydrins compared to nonfluorinated alcohols","volume":"51","author":"Graton","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118332_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169383","article-title":"Structural basis of novel bile acid-based modulators of FXR","volume":"437","author":"Kydd-Sinclair","year":"2025","journal-title":"J. Mol. Biol."},{"issue":"19","key":"10.1016\/j.ejmech.2025.118332_bib82","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1021\/acs.jmedchem.6b01126","article-title":"Discovery of 3\u03b1,7\u03b1,11\u03b2-Trihydroxy-6\u03b1-ethyl-5\u03b2-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders","volume":"59","author":"Pellicciari","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpba.2013.06.029","article-title":"Determination of bile salt critical micellization concentration on the road to drug discovery","volume":"87","author":"Natalini","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118332_bib84","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114903","article-title":"Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD","volume":"245","author":"Qin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115614","article-title":"Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists","volume":"258","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107940","article-title":"Design, synthesis and FXR partial agonistic activity of anthranilic acid derivatives bearing aryloxy moiety as therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"153","author":"Chen","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115307","article-title":"Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease","volume":"252","author":"Qin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105198","article-title":"Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene","volume":"115","author":"Qiu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117238","article-title":"Discovery of FXR\/PPARgamma dual partial agonist","volume":"85","author":"Yamashita","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118013","article-title":"Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR\/PPAR\u03b4 agonists for treatment of pulmonary fibrosis","volume":"298","author":"Yue","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117073","article-title":"Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone","volume":"75","author":"Huang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118332_bib93","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","article-title":"A dual modulator of Farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis","volume":"60","author":"Schmidt","year":"2017","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118332_bib94","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1021\/acs.jmedchem.1c00831","article-title":"Second-Generation dual FXR\/sEH modulators with optimized pharmacokinetics","volume":"64","author":"Helmstadter","year":"2021","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118332_bib95","doi-asserted-by":"crossref","first-page":"18334","DOI":"10.1021\/acs.jmedchem.4c01651","article-title":"Design, synthesis, and pharmacological evaluation of dual FXR-LIFR modulators for the treatment of liver fibrosis","volume":"67","author":"Rapacciuolo","year":"2024","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118332_bib96","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic Fatty liver disease","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118332_bib97","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/acs.jmedchem.4c02720","article-title":"Discovery of first-in-class FXR and HSD17B13 dual modulator for the treatment of Metabolic dysfunction-associated Fatty liver disease","volume":"68","author":"Jiao","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118332_bib98","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1021\/acs.jmedchem.5c00539","article-title":"Dual Modulator of FXR and HSD17B13: revitalizing FXR therapies in MASH","volume":"68","author":"Wei","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118332_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107852","article-title":"Discovery of the FXR\/CES2 dual modulator LE-77 for the treatment of irinotecan-induced delayed diarrhea","volume":"153","author":"Cao","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jsbmb.2004.11.012","article-title":"5beta-Cholane activators of the farnesol X receptor","volume":"94","author":"Fukuchi","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118332_bib101","series-title":"Preparation of Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-mediated Diseases or Conditions","author":"Pellicciari","year":"2008"},{"key":"10.1016\/j.ejmech.2025.118332_bib102","series-title":"Preparation of Heterocyclic FXR Binding Compounds","author":"Kremoser","year":"2008"},{"key":"10.1016\/j.ejmech.2025.118332_bib103","series-title":"Preparation of Substituted Methoxyphenylcyclopropane Derivatives for Use as NR1 H4 Receptor Agonists Useful in Treatment and Prophylaxis of FXR-mediated Diseases","author":"Kremoser","year":"2011"},{"key":"10.1016\/j.ejmech.2025.118332_bib104","series-title":"Novel FXR (NR1H4) Binding and Activity Modulating Compounds","author":"Kinzel","year":"2013"},{"key":"10.1016\/j.ejmech.2025.118332_bib105","series-title":"Methods for Using Farnesoid X Receptor (FXR) Agonists for Treating or Preventing Liver Diseases and Disorders","author":"Laffitte","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib106","series-title":"Methods for Preventing or Treating Liver Diseases Mediated by Farnesoid X Receptor Agonists. WO2017145041","author":"Laffitte","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib107","series-title":"Methods for Using FXR Agonists for Treatment of Gastrointestinal or Liver Disease","author":"Laffitte","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib108","series-title":"Preparation of Isoxazolyl Compounds as FXR Modulators and Methods of their Use","author":"Wang","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib109","series-title":"Preparation of Isoxazole-based Compounds Useful in Modulating the Farnesoid X Receptor (FXR)","author":"Sharma","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118332_bib110","series-title":"Farnesoid X Receptor (FXR) Modulating Compounds and Methods of their Preparation and Use for Treating Disorders Associated with FXR","author":"Judkins","year":"2021"},{"key":"10.1016\/j.ejmech.2025.118332_bib111","series-title":"N-Aryl Carboxamides as Farnesoid X Receptor Agonists and their Preparation","author":"Smith","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib112","series-title":"N-Aryl and N-heteroaryl Carboxamides as Farnesoid X Receptor Agonists and their Preparation","author":"Smith","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib113","series-title":"N-Aryl Carboxamides as Farnesoid X Receptor Agonists and their Preparation","author":"Smith","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118332_bib114","series-title":"Substituted Amide Compounds as Farnesoid X Receptor Modulators and their Preparation","author":"Wacker","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118332_bib115","series-title":"Substituted Bicyclic Compounds as Farnesoid X Receptor Modulators and their Preparation","author":"Wacker","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118332_bib116","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118332_bib117","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118332_bib119","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/hep.26786","article-title":"Bile acids reach out to the spinal cord: new insights to the pathogenesis of itch and analgesia in cholestatic liver disease","volume":"59","author":"Dawson","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118332_bib120","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118332_bib121","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118332_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696784","article-title":"Th2 Modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis","volume":"12","author":"Meng","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118332_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/ph16121707","article-title":"Targeting Transient Receptor Potential (TRP) channels, Mas-Related G-Protein-Coupled receptors (Mrgprs), and protease-activated receptors (PARs) to relieve itch","volume":"16","author":"Tsagareli","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"7887","key":"10.1016\/j.ejmech.2025.118332_bib124","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118332_bib125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/13543776.2024.2314296","article-title":"Patented Farnesoid X receptor modulators: a review (2019 - present)","volume":"34","author":"Gioiello","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118332_bib126","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","article-title":"Network pharmacology: curing causal mechanisms instead of treating symptoms","volume":"43","author":"Nogales","year":"2022","journal-title":"Trends Pharmacol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:58:25Z","timestamp":1780909105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":126,"alternative-id":["S0223523425010979"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118332","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FXR-targeted drug discovery: Recent advances and therapeutic perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118332"}}